AIS Healthcare Continues Expansion of Critical Infusion Therapies
Image by xb100 on Freepik
AIS Healthcare, the leading provider of targeted drug delivery and infusion care solutions in the United States and the parent company of Advanced Infusion Care (AIC), announced on August 14th the opening of a new AIC pharmacy in Cockeysville, Maryland. The announcement marks the third expansion for AIC in the past five months. Earlier in August, AIC announced an expansion of its nursing and in-home care footprint in the Northeast. The company also reopened a newly designed pharmacy in Valdosta, Georgia, in April.
"We are thrilled to open a pharmacy location in Maryland. This expansion is a testament to AIC’s unwavering dedication to our patients and our vision of providing best-in-class health care services with a personal touch. By opening this location, we aim to streamline the medication fulfillment process, enhance convenience, and ultimately improve the lives of our patients,” said AIC President Jud Hall in a press release.
The Maryland location marks the sixth facility from which AIC can dispense essential medications and personalized care to patients with complex medical needs.
The announcement of the new Maryland pharmacy came just a week after AIC expanded its nursing and home-infusion care capabilities to cover Rhode Island, Connecticut, and Massachusetts, solidifying AIC’s presence in New England.
"Our growth into the New England market will allow AIC’s talented team of infusion nurse specialists to support even more patients," Hall added. “Our team of nationally accredited home infusion specialists will help ensure each individual’s specific clinical and personal needs are met, driving better outcomes for all of our patients."
The initial groundwork for this expansion was set in April, as AIC opened a newly designed pharmacy in Valdosta. Hall said the facility would “enhance our industry-leading regulatory compliance, quality and operational flow allowing for sustained growth and expansion into new markets.”
Hall said the new facility would also “expand production and ultimately boost staff efficiency.”
A Meaningful Expansion
While AIC’s expansion is good news for the company, it is also decidedly good news for patients who rely on the provider’s infusion care treatments to manage their immunodeficiencies and other complex health needs.
AIC works with individuals who face a variety of primary immunodeficiencies and autoimmune disorders, many of whom struggle with debilitating symptoms and require immunoglobulin therapy to maintain their immune systems and fight infections.
With the expansion into New England, AIC provides people access to local infusion care and bespoke treatment options, as well as 24/7 access to a dedicated team of clinical and support staff. They include clinical pharmacists, intake managers, and infusion nurse specialists who provide in-home infusion care along with self-infusion and infusion pump training.
AIC’s team of medical professionals work closely with patients to provide the best possible care, a fact reflected in a 99% satisfaction rate for in-home care and 97% of patients having a high adherence to their medication. AIS Healthcare has also been recognized by top independent industry accreditors, URAC and the Accreditation Commission for Health Care (ACHC), further highlighting the excellence of the company’s pharmacy and nursing services.
To that end, AIC’s increased presence in more regions means patients have more access to various treatment options, as well as a trusted and accredited partner for them to work with to get the medication they need, delivered safely and effectively. As 80% of those living with primary immunodeficiencies around the world lack access to adequate healthcare, AIC’s expansion has the potential to be life-saving.
Increasing Access to Critical Treatments
In addition to the recent expansions, AIC continues to add to the list of infusion treatments they offer. AIC currently offers 15 different immunoglobulin treatments including LEQEMBI™, which is approved by the Food and Drug Administration for intravenous use in treating Alzheimer’s disease, and GAMMAKED™, developed by Kedrion for the treatment of patients with primary humoral immunodeficiency (PI), idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
AIC’s esteemed on-staff nurses ensure all patients and caregivers have the proper training to administer intravenous and subcutaneous medication. Patients are also provided 24/7 access to a nurse or pharmacist, who can provide information on their specific condition and treatment as well as medication management and care coordination services.
For patient safety, every AIC nurse wears personal protective equipment and follows all relevant health and safety guidelines. While rarely needed, all AIC nurses have training to handle potential medical emergencies if they arise during treatment.
With the New England expansion extending its network into 40 states with over 2,000 patients served, AIC continues to fulfill its vision of setting the standard for infusion care.
“At AIS Healthcare, we have developed our business around a center of excellence model, where we have dedicated resources that focus on enhancing the quality of care we provide our patients,” AIS Healthcare’s Chief Executive Officer Simon Castellanos said in a press release, “We believe that our commitment to safety and quality is a key differentiator for us and is difficult to replicate in the market.”